NCT07015697 - A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Recurrent or Metastatic Solid Tumors

Interventions

DRUG

Trastuzumab Deruxtecan

"Dose Escalation Part: Trastuzumab Deruxtecan will be administered at escalating doses to determine the RDE.~Expansion Part: Trastuzumab Deruxtecan will be administered at RDE."

Trial Locations (5)

37203

RECRUITING

Research Site, Nashville

43537

RECRUITING

Research Site, Maumee

104-0045

RECRUITING

Research Site, Tokyo

135-8550

RECRUITING

Research Site, Tokyo

142-8666

RECRUITING

Research Site, Tokyo